Bionova Capital
Bionova Capital is a now-closed, Lisbon-based venture capital firm that invested in early-stage healthcare startups across Europe from its 2015 founding, led by Chairman Peter Villax.
- Company typePrivate
- Founded2015
- HeadquartersLisbon, Portugal
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Bionova Capital does
Bionova Capital is a Lisbon-based venture capital firm that historically focused on healthcare and invested in early-stage startups across Europe. The firm was founded in 2015 and operated with a small team of 1-10 employees, led by Peter Villax in the role of Chairman.
The firm's investment activity centered on co-investing in technology and life-sciences companies, with documented participation alongside Innvierte (the co-investment vehicle of CDTI Innovación, Spain's public innovation financing agency). In October 2025, Innvierte deployed €8.644 million across six co-investment operations spanning healthcare technology, biotech, market intelligence, data security, biogas, and satellite launch — with Bionova Capital participating in the deal flow. This partnership evidences cross-border Iberian collaboration rather than independent fund deployment.
As of the most recent data, Bionova Capital has closed operations. The corporate website (bionovacapital.com) returns only a verification/loading placeholder rather than active content, no management roster beyond the Chairman role is publicly documented, and no fund size, AUM, portfolio company list, or revenue figures have been disclosed. The firm should be regarded as a defunct entity for analytical purposes.
Bionova Capital firmographics
Firmographics- Name
- Bionova Capital
- Website
- https://bionovacapital.com
- Company type
- Private
- Founded year
- 2015
- Headcount range
- 1–10 employees
- Short description
- Bionova Capital is a now-closed, Lisbon-based venture capital firm that invested in early-stage healthcare startups across Europe from its 2015 founding, led by Chairman Peter Villax.
- Ownership category
- akta.pro rank
Bionova Capital industry classification
Industry- Product category
- Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
- akta.pro secondary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where Bionova Capital is headquartered
LocationHeadquarters
- HQ city
- Lisbon
- HQ country
- Portugal
- HQ region
- Europe
Markets served
Bionova Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales
Bionova Capital product offering
Product offeringCore offering
Bionova Capital was a healthcare-focused venture capital firm that invested in early-stage startups across Europe. The firm deployed capital into healthcare technology, biotech, and related life sciences companies, including through co-investment operations alongside Spain's Innvierte (CDTI Innovación) program.
Differentiator
Problem solved
Functional benefit
Products and services
- Early-stage healthcare venture capital funding
- Co-investment operations with Innvierte (CDTI Innovación) Joint equity investment operations executed alongside Spain's Innvierte (under CDTI Innovación) program, targeting Spanish technology and innovation companies in healthcare technology, biotech, and adjacent sectors. Targeted at co-investees and Spanish technology companies.
Companies that use Bionova Capital
Customer profileIdeal customer profiles1 record
Bionova Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Bionova Capital partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Bionova Capital competitors and assessment
Company assessmentDirect peers
- Ysios Capital: Spanish-based specialist venture capital firm investing in early- and mid-stage life sciences companies; highly comparable in Iberian and pan-European healthcare focus.
- Health Ventures: Portugal-based healthcare-focused early-stage investor with a similar Lisbon-rooted, European-mandate thesis; competes directly for Iberian healthcare deal flow.
- BioGeneration Ventures: Dutch-based early-stage biotech and life sciences VC; directly comparable as a European, healthcare-vertical-focused early-stage fund with a similar company-creation approach.
- Kurma Partners: Paris-based healthcare and biotechnology venture investor spanning early- and growth-stage European healthcare; closely comparable in mandate, stage focus, and continental deal sourcing.
- Sunstone Capital: Copenhagen-based early-stage European investor with explicit life sciences and healthcare exposure; comparable in stage and vertical focus.
- Andera Partners (Life Sciences): Paris-based European private equity firm with a dedicated Life Sciences franchise investing in biotech, medtech, and digital health; comparable in stage and sector mandate.
Broad incumbents
- Forbion: Established European life sciences investor with multi-billion AUM across early- and growth-stage biotech; comparable as a sector-focused VC operating in the same healthcare vertical at significantly greater scale.
- Novo Seeds: Early-stage healthcare and biotech investment arm of Novo Holdings; comparable as a sector-specialist European VC anchored to a larger capital base.
- LSP (Life Sciences Partners): Long-standing European healthcare and life sciences investor across public and private stages; overlaps with Bionova's healthcare vertical thesis at a meaningfully larger scale.
- GIMV: Belgian-listed European investment company with a healthcare-focused platform alongside broader tech investments; overlaps with Bionova on European healthcare deal flow.
Market position
Strengths2 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Bionova Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bionova Capital leadership team
Management profileNumber of profiles
Profiles1 record
Bionova Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bionova Capital M&A and investment
M&A and investmentM&A
Investments9 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bionova Capital
What does Bionova Capital do?
Bionova Capital was a healthcare-focused venture capital firm that invested in early-stage startups across Europe. The firm deployed capital into healthcare technology, biotech, and related life sciences companies, including through co-investment operations alongside Spain's Innvierte (CDTI Innovación) program.
When was Bionova Capital founded?
Bionova Capital was founded in 2015. It employs 1 to 10 people.
Where is Bionova Capital based?
Bionova Capital is headquartered in Lisbon, Portugal, in the Europe region.
Who are Bionova Capital's main competitors?
Direct peers on record are Ysios Capital, Health Ventures, BioGeneration Ventures, Kurma Partners, Sunstone Capital and Andera Partners (Life Sciences). Broad incumbents are Forbion, Novo Seeds, LSP (Life Sciences Partners) and GIMV.
Does Bionova Capital have an API?
No public API is recorded for Bionova Capital.
What industry is Bionova Capital in?
Bionova Capital's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.